Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 23, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On October 22, 2003, Abacus (GSK) Trustees Limited transferred 12,648 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on October 23, 2003.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, directors Dr. J-P Garnier and Mr. J D Coombe hold an interest in the shares held by the trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Investor Verification Checklist
- Verify the total number of shares transferred (12,648) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the status of directors Dr. J-P Garnier and Mr. J D Coombe regarding their indirect interest in the GSK Trust.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.